Danaher Corporation (DHR)
Insights Into Danaher (DHR) Q4: Wall Street Projections for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Danaher (DHR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?
DHR is set to report Q4 results on Jan. 28, with revenues seen up 3.9% and bioprocessing and diagnostics strength in focus.
Danaher (DHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Danaher: Biotech Strength And Cash Generation Reinforce A $250 Fair Value
Danaher Corporation is rated Buy with a target price of $250, implying 10.5% upside from $226.25. DHR's strong Q3 execution featured 4.5% revenue growth, margin expansion to 37.2%, and robust free cash flow conversion at 145%. Biotechnology drives growth while Life Sciences stagnates; management guides for modest FY25 growth and margin expansion in 2026.
Danaher (DHR) Up 2% Since Last Earnings Report: Can It Continue?
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Danaher Corporation (DHR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Danaher Corporation ( DHR ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Rainer Blair - President, CEO & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division I think we'll kick it off. Welcome, everybody.
The Richest 0.1% Are Buying These 3 Dividend Stocks Right Now
When ultra-rich investors start coalescing into the same names or put an unusually large amount of money into a single stock, that should raise more interest.
Danaher Q3 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR Q3 earnings and sales beat estimates, driven by solid segment growth and stronger operating margins.
Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript
Danaher Corporation (NYSE:DHR ) Q3 2025 Earnings Call October 21, 2025 8:00 AM EDT Company Participants John Bedford - Vice President of Investor Relations Rainer Blair - President, CEO & Director Matt McGrew - CFO & Executive VP Conference Call Participants Michael Ryskin - BofA Securities, Research Division Tycho Peterson - Jefferies LLC, Research Division Scott Davis - Melius Research LLC Douglas Schenkel - Wolfe Research, LLC Vijay Kumar - Evercore ISI Institutional Equities, Research Division Daniel Brennan - TD Cowen, Research Division Jack Meehan - Nephron Research LLC Puneet Souda - Leerink Partners LLC, Research Division Presentation Operator My name is David, and I'll be your conference facilitator this morning. At this time, I'd like to welcome everyone to Danaher Corporation's Third Quarter 2025 Earnings Results Conference Call.
Danaher beats quarterly estimates on strength in diagnostic tools and tech
Life Sciences firm Danaher on Tuesday beat Wall Street's third-quarter profit and revenue estimates, buoyed by resilient demand for its diagnostic testing tools and services, sending its shares up 1.3% in premarket trading.
LH vs. DHR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
